Clinical Trial

The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-04.
Trial Details
NCT Number NCT07289750
Lead Sponsor The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Conditions T2DM, MAFLD
Enrollment 80 participants
Start Date 2026-05-01
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-24